Search Results - "Johnson, A O"

Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations by Ahmedzai, S, Balfour-Lynn, I M, Bewick, T, Buchdahl, R, Coker, R K, Cummin, A R, Gradwell, D P, Howard, L, Innes, J A, Johnson, A O C, Lim, E, Lim, Wei Shen, McKinlay, K P, Partridge, M R, Popplestone, M, Pozniak, A, Robson, A, Shovlin, C L, Shrikrishna, D, Simonds, A, Tait, P, Thomas, M

Get more information

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials by Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson-Levonas, A. O., Brudi, P.

“…Aim: This post hoc analysis compared the lipid‐altering efficacy and safety of ezetimibe 10 mg plus statin (EZE/statin) vs. statin monotherapy in…”
Get full text

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus by Reasner, C., Olansky, L., Seck, T. L., Williams-Herman, D. E., Chen, M., Terranella, L., Johnson-Levonas, A. O., Kaufman, K. D., Goldstein, B. J.

“…Aims: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed‐dose combination of sitagliptin and…”
Get full text

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study by Farnier, M, Averna, M, Missault, L, Vaverkova, H, Viigimaa, M, Massaad, R, Vandormael, K, Johnson-Levonas, A O, Brudi, P

“…To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg vs. rosuvastatin (ROSUVA) 10 mg. In this…”
Get more information

one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes by Kipnes, M.S, Hollander, P, Fujioka, K, Gantz, I, Seck, T, Erondu, N, Shentu, Y, Lu, K, Suryawanshi, S, Chou, M, Johnson-Levonas, A.O, Heymsfield, S.B, Shapiro, D, Kaufman, K.D, Amatruda, J.M

“…Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM). Methods: This was a multicenter,…”
Get full text

Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study by Lütjohann, D, von Bergmann, K, Sirah, W, Macdonell, G, Johnson-Levonas, A O, Shah, A, Lin, J, Sapre, A, Musliner, T

“…To assess the long-term efficacy and safety profile of ezetimibe 10 mg/day in patients with homozygous sitosterolemia. This was an extension of a multi-centre,…”
Get more information

Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease by Barrios, V, Amabile, N, Paganelli, F, Chen, J-W, Allen, C, Johnson-Levonas, A O, Massaad, R, Vandormael, K

“…This randomised, double-blind study evaluated the efficacy and safety of ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg tablet compared to doubling the…”
Get more information

Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease by Cruz-Fernández, J M, Bedarida, G V, Adgey, J, Allen, C, Johnson-Levonas, A O, Massaad, R

“…This randomised, double-blind, placebo (PBO)-controlled study evaluated the efficacy and safety of ezetimibe (EZE) co-administered with ongoing atorvastatin…”
Get more information

Postoperative mortality and complications in patients with and without pre-operative SARS-CoV-2 infection: a service evaluation of 24 million linked records using OpenSAFELY by McInerney, C D, Kotzé, A, Bacon, S, Cutting, J E, Fisher, L, Goldacre, B, Johnson, O A, Kua, J, McGuckin, D, Mehrkar, A, Moonesinghe, S R

“…Surgical decision-making after SARS-CoV-2 infection is influenced by the presence of comorbidity, infection severity and whether the surgical problem is…”
Get full text

Chronic opioid use: a risk factor for central sleep apnoea and successful therapy with adaptive pressure support servo-ventilation by Fahim, A, Johnson, A O

“…Sleep apnoea is a global health problem with significant morbidity. Obesity is a well-known risk factor for this condition, however chronic intake of opioids…”
Get full text

Dental Extractions under General Anesthesia: New Insights from Process Mining by Fox, F., Whelton, H., Johnson, O.A., Aggarwal, V.R.

“…Introduction: Tooth extraction under general anesthetic (GA) is a global health problem. It is expensive, high risk, and resource intensive, and its prevalence…”
Get full text

clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study by Proietto, J, Rissanen, A, Harp, J.B, Erondu, N, Yu, Q, Suryawanshi, S, Jones, M.E, Johnson-Levonas, A.O, Heymsfield, S.B, Kaufman, K.D, Amatruda, J.M

“…Objective: To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients. Design:…”
Get full text

A di-leucine sequence and a cluster of acidic amino acids are required for dynamic retention in the endosomal recycling compartment of fibroblasts by Johnson, A O, Lampson, M A, McGraw, T E

“…Insulin-regulated aminopeptidase (IRAP), a transmembrane aminopeptidase, is dynamically retained within the endosomal compartment of fibroblasts. The…”
Get full text

Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus by Constance, C, Westphal, S, Chung, N, Lund, M, McCrary Sisk, C, Johnson-Levonas, A.O, Massaad, R, Allen, C

“…This randomized, double-blind study evaluated the efficacy of switching from atorvastatin (ATV) 10 mg to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg, EZE/SIMVA…”
Get full text

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study by Reckless, J P D, Henry, P, Pomykaj, T, Lim, S T, Massaad, R, Vandormael, K, Johnson-Levonas, A O, Lis, K, Brudi, P, Allen, C

“…The aim of this study was to investigate the efficacy and safety profile of switching to ezetimibe/simvastatin (Eze/Simva) 10/40 mg compared with doubling the…”
Get more information

Correlation of lactose maldigestion, lactose intolerance, and milk intolerance by Johnson, AO, Semenya, JG, Buchowski, MS, Enwonwu, CO, Scrimshaw, NS

“…Lactose digestion and tolerance were evaluated in 164 African Americans ranging in age from 12 to 40 y who claimed intolerance to one cup (240 mL) or less of…”
Get full text

Transferrin Receptor Containing the SDYQRL Motif of TGN38 Causes a Reorganization of the Recycling Compartment but Is Not Targeted to the TGN by Johnson, A. O., Ghosh, R. N., Dunn, K. W., Garippa, R., Park, J., Mayor, S., Maxfield, F. R., McGraw, T. E.

“…The SDYQRL motif of the cytoplasmic domain of TGN38 is involved in targeting TGN38 from endosomes to the TGN. To create a system for studying this pathway, we…”
Get full text

Adaptation of lactose maldigesters to continued milk intakes by Johnson, AO, Semenya, JG, Buchowski, MS, Enwonwu, CO, Scrimshaw, NS

“…Twenty-five lactose-maldigesting and lactose-intolerant African Americans, ranging in age from 13 to 39 y, were given gradually increasing amounts of lactose…”
Get full text

Hepatocellular carcinoma in Nigerian children by AKINYINKA, O. O, FALADE, A. G, OGUNBIYI, O, JOHNSON, A. O. K

“…Childhood primary hepatocellular carcinoma is rare and accounts for less than 1% of all abdominal malignancies in children < or = 14 years of age. A review of…”
Get full text

Speaking and interruptions during primary care office visits by Rhoades, D R, McFarland, K F, Finch, W H, Johnson, A O

“…Patients and physicians value effective communication and consider it an essential part of the medical encounter. This study examined physician-patient…”
Get full text